Patents Examined by Ilia I Ouspenski
  • Patent number: 11945871
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: April 2, 2024
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
  • Patent number: 11905327
    Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: February 20, 2024
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Wang Zhang, Shu Wu, Shuai Yang, Qi Pan, Chuan-Chu Chou
  • Patent number: 11903973
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: February 20, 2024
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Patent number: 11905334
    Abstract: It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: February 20, 2024
    Inventors: Byoung S. Kwon, Hye Jeong Kim, Sunhee Hwang, Joongwon Lee, Seung Hyun Lee, Sun Woo Im, Jin Kyung Choi, Hyun Tae Son, Hyeok-Jun Park
  • Patent number: 11899019
    Abstract: Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: February 13, 2024
    Assignees: J-PHARMA CO., LTD., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Hitoshi Endou, Goshi Ishihara, Kyoichi Kaira, Yoshikatsu Kanai
  • Patent number: 11899017
    Abstract: The present disclosure relates to the finding that the ratio of circulating (i.e., peripheral blood) central memory T cells to circulating effector T cells in a cancer patient can predict whether a tumor has an inflammatory milieu or not. In addition, since having an inflammatory milieu (“hot tumor”) is a positive factor for responding to checkpoint inhibitors, e.g., PD-1 antagonists, this assay on peripheral blood can also be used to predict a response to a checkpoint inhibitor, e.g., an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or an antibody or an antigen binding portion thereof that binds specifically to PD-1 ligand 1 (PD-L1) and inhibits PD-L1 activity.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: February 13, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nataly Manjarrez Orduño, Suzanne J. Suchard
  • Patent number: 11897955
    Abstract: A monoclonal antibody or a derivative thereof that binds to a human TIGIT antigen with high-affinity and antagonistically inhibits the binding of TIGIT to a ligand thereof such as CD155 is provided. Amino acid sequences of antigen complementarity-determining regions CDR-L1, CDR-L2 and CDR-L3 of an antibody light chain variable region, and amino acid sequences of antigen complementarity-determining regions CDR-H1, CDR-H2 and CDR-H3 of an antibody heavy chain variable region are specified. Further, a humanization preparation method for the antibody and amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody are provided. The antibody or the derivative thereof can serve as an ingredient of a pharmaceutical composition or can be prepared into an appropriate drug preparation, and administered alone or in combination with other medications, such as an anti-PD-1 monoclonal antibody, or treatment means, for treating diseases such as tumors.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: February 13, 2024
    Assignee: ACROIMMUNE BIOTECH CO., LTD.
    Inventors: Qunmin Zhou, Weiwei Sun, Zui Chen, Xiaoxiao Ma, Jinling Fan, Hongqun Hu
  • Patent number: 11884737
    Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: January 30, 2024
    Assignees: UCB BIOPHARMA SRL, BIOGEN MA INC.
    Inventors: Ruth Oliver, Miren Zamacona
  • Patent number: 11884724
    Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: January 30, 2024
    Assignee: Merck Patent GmbH
    Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
  • Patent number: 11884727
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 30, 2024
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 11884728
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 30, 2024
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 11878058
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: January 23, 2024
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
  • Patent number: 11866494
    Abstract: The present disclosure relates to compositions and methods for enhancing CAR T therapy through uses of co-stimulation. Some embodiments relate to an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR) and an agent associated with a co-stimulatory molecule, the CAR comprising an intracellular domain of a costimulatory molecule.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: January 9, 2024
    Assignee: Innovative Cellular Therapeutics Holdings, Ltd.
    Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao, Zhao Wu
  • Patent number: 11866510
    Abstract: The invention relates to chimeric antigen receptors (CAR) that comprise one or more single human variable domain antibody and cells that express such CAR. In particular, the invention relates to CARs that include multiple single human variable domain antibodies. In a particular embodiment, the one or more single human variable domain antibody binds to prostate membrane antigen.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: January 9, 2024
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Brian McGuinness, Colette Johnston
  • Patent number: 11860161
    Abstract: Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: January 2, 2024
    Assignee: Seattle Children's Hospital
    Inventors: Neelufar Mozaffarian, Anne M. Stevens
  • Patent number: 11858997
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: January 2, 2024
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Patent number: 11858996
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 2, 2024
    Assignee: KYMAB LIMITED
    Inventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Volker Germaschewski, Ian Kirby, Miha Kosmac, Nahida Parveen, Robert Rowlands, Gwenoline Borhis
  • Patent number: 11834505
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 5, 2023
    Assignee: Checkpoint Therapeutics, Inc.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • Patent number: 11827706
    Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: November 28, 2023
    Inventors: Rajesh Narwal, David Fairman, Paul Robbins, Meina Liang, Amy Schneider, Carlos Chavez, Carina Herl, Min Pak, Hong Lu, Marlon Rebelatto, Keith Steele, Anmarie Boutrin, Li Shi, Shengyan Hong, Brandon Higgs, Lorin Roskos
  • Patent number: 11814431
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: November 14, 2023
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt